Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILB-3101 in advanced solid tumors
NCT06426680Phase 1Recruiting
- Sponsor
- Innolake Biopharm
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ILB-3101 in solid tumor (advanced stage), sponsored by Innolake Biopharm. Primary endpoints: Dose-Limiting Toxicities at Day 21 and Maximum Tolerated Dose at Day 21. Started Oct 2024; status: recruiting.
02
Drugs
ILB-3101
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06426680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06426680.